Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Nrf2 Pathway Activators market size was valued at USD 6120.95 million in 2022 and is expected to expand at a CAGR of 4.23% during the forecast period, reaching USD 7848.29 million by 2028.
Nrf2 (nuclear factor erythroid-2-related factor 2) is a transcription factor that activates over 500 genes via molecules called sirtuins. Nrf2 activation can be achieved through exercise, calorie restriction (including fasting) and ingestion of natural nutrients that are NRF2 activators.
Influence of COVID-19 Outbreak on Nrf2 Pathway Activators Industry Development
Clinical trials are an extremely important part of life science research. Only through clinical trials can products enter the market and become commodities. The epidemic has caused an irreversible obstacle to a large number of enterprises, and will also pose a huge challenge to the Nrf2 Pathway Activators industry.
Initially, during the COVID-19 period, all R&D and production resources are concentrated on the production of anti-epidemic drugs and vaccines and other related products. In a short period of time, the production and R&D of the Nrf2 industry may be ignored. In addition, the second wave of epidemics once again reached Europe and North America, and the number of hospitalizations and deaths due to COVID-19 is also increasing rapidly. In response to the recurrence of the epidemic, European and American countries are stepping up their efforts to prevent the epidemic, and stricter epidemic prevention and control measures will be implemented again. Strict epidemic prevention and control measures will affect the flow of people and activities, and in turn affect logistics, causing the production of the pharmaceutical industry to be impacted due to the supply of raw materials and labor shortages.
Market Driver Analysis
Oxidative stress is induced by the imbalance of the redox state in the body and involves excessive accumulation of reactive oxygen species (ROS) or dysfunction of the antioxidant system. In the short term, oxidative stress is unlikely to be harmful, because although the body may be temporarily overwhelmed, it usually responds and removes any harmful compounds. However, chronic oxidative stress is associated with a variety of diseases, including Parkinson's disease, Alzheimer's disease, cardiovascular disease, and several types of cancer.
Take Alzheimer's disease as an example. Numerous studies have shown that compared with normal brains, the content of Nrf2 in the brain of Alzheimer's disease patients decreases, and the oxidative stress increases significantly. Oxidative stress can cause the deposition of amyloid in the brain, and Apeptide deposition can aggravate oxidative stress, leading to the occurrence and development of Alzheimer's disease. The Keap1-Nrf2-ARE signaling pathway is an important regulatory pathway for maintaining redox homeostasis in the body. Nrf2 activators can increase the content of Nrf2 in the brain, induce the transcription of cytoprotective genes, reduce oxidative stress, and improve the symptoms of Alzheimer's disease. It can be used as a treatment for Alzheimer's. Candidate compounds for the disease. Only a more comprehensive and in-depth development of Nrf2 study can more effectively develop new drugs for the treatment of Alzheimer's disease. With the increasing incidence of such OS diseases, Nrf2 pathway activators will also receive more and more attention.
Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via hormesis in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.
Awareness of anti-cell-senescence from the increasing geriatric population across the world and generation Y have been raise. And the awareness has been accelerating many anti-aging products' development.
Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via heresies in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.
Region Overview:
North America had the highest growth rate of all regions.
Company Overview:
Biogen is one of the major players operating in the Nrf2 Pathway Activators market, holding a share of 82.23% in 2020.
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
Reata Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various life-threatening diseases.
Segmentation Overview:
Among different product types, Dimethyl Fumarate segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Pharmaceutical segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Nrf2 Pathway Activators industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Nrf2 Pathway Activators. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Nrf2 Pathway Activators Market Report Include:
Market Size Estimates: Nrf2 Pathway Activators market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Nrf2 Pathway Activators market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Nrf2 Pathway Activators market
Segment Market Analysis: Nrf2 Pathway Activators market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Nrf2 Pathway Activators market situations and prospects in major and top regions and countries
Nrf2 Pathway Activators Market
Nrf2 Pathway Activators Industry Chain: Nrf2 Pathway Activators market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Nrf2 Pathway Activators Industry News, Policies by regions
Nrf2 Pathway Activators Industry Porters Five Forces Analysis
Key players in the global Nrf2 Pathway Activators market are covered in Chapter 2:
Reata Pharmaceuticals
Cayman Chemical Company
BioVision Inc
Biogen
BOC Sciences
Abcam
Biophore
In Chapter 6 and Chapter 9, on the basis of types, the Nrf2 Pathway Activators market from 2018 to 2028 is primarily split into:
Dimethyl Fumarate
4-Octyl Itaconate
Bardoxolone
Other
In Chapter 7 and Chapter 10, on the basis of applications, the Nrf2 Pathway Activators market from 2018 to 2028 covers:
Pharmaceutical
Laboratory
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Nrf2 Pathway Activators market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Nrf2 Pathway Activators industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Nrf2 Pathway Activators market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Nrf2 Pathway Activators industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Nrf2 Pathway Activators market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Nrf2 Pathway Activators market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Nrf2 Pathway Activators market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Nrf2 (nuclear factor erythroid-2-related factor 2) is a transcription factor that activates over 500 genes via molecules called sirtuins. Nrf2 activation can be achieved through exercise, calorie restriction (including fasting) and ingestion of natural nutrients that are NRF2 activators.
Influence of COVID-19 Outbreak on Nrf2 Pathway Activators Industry Development
Clinical trials are an extremely important part of life science research. Only through clinical trials can products enter the market and become commodities. The epidemic has caused an irreversible obstacle to a large number of enterprises, and will also pose a huge challenge to the Nrf2 Pathway Activators industry.
Initially, during the COVID-19 period, all R&D and production resources are concentrated on the production of anti-epidemic drugs and vaccines and other related products. In a short period of time, the production and R&D of the Nrf2 industry may be ignored. In addition, the second wave of epidemics once again reached Europe and North America, and the number of hospitalizations and deaths due to COVID-19 is also increasing rapidly. In response to the recurrence of the epidemic, European and American countries are stepping up their efforts to prevent the epidemic, and stricter epidemic prevention and control measures will be implemented again. Strict epidemic prevention and control measures will affect the flow of people and activities, and in turn affect logistics, causing the production of the pharmaceutical industry to be impacted due to the supply of raw materials and labor shortages.
Market Driver Analysis
Oxidative stress is induced by the imbalance of the redox state in the body and involves excessive accumulation of reactive oxygen species (ROS) or dysfunction of the antioxidant system. In the short term, oxidative stress is unlikely to be harmful, because although the body may be temporarily overwhelmed, it usually responds and removes any harmful compounds. However, chronic oxidative stress is associated with a variety of diseases, including Parkinson's disease, Alzheimer's disease, cardiovascular disease, and several types of cancer.
Take Alzheimer's disease as an example. Numerous studies have shown that compared with normal brains, the content of Nrf2 in the brain of Alzheimer's disease patients decreases, and the oxidative stress increases significantly. Oxidative stress can cause the deposition of amyloid in the brain, and Apeptide deposition can aggravate oxidative stress, leading to the occurrence and development of Alzheimer's disease. The Keap1-Nrf2-ARE signaling pathway is an important regulatory pathway for maintaining redox homeostasis in the body. Nrf2 activators can increase the content of Nrf2 in the brain, induce the transcription of cytoprotective genes, reduce oxidative stress, and improve the symptoms of Alzheimer's disease. It can be used as a treatment for Alzheimer's. Candidate compounds for the disease. Only a more comprehensive and in-depth development of Nrf2 study can more effectively develop new drugs for the treatment of Alzheimer's disease. With the increasing incidence of such OS diseases, Nrf2 pathway activators will also receive more and more attention.
Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via hormesis in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.
Awareness of anti-cell-senescence from the increasing geriatric population across the world and generation Y have been raise. And the awareness has been accelerating many anti-aging products' development.
Some scientists believe the transcription factor nrf2 regulates levels of antioxidant proteins, a part of the response to everyday cellular stress, such as that induced by raised mitochondrial activity and greater generation of reactive oxygen species (ROS) during exercise. Greater nrf2 activity shows up in long-lived species and in the modest slowing of aging that can be achieved via heresies in some species. So the R&D about the Nrf2 pathway activators will earn more attention in the forecast period, which will largely help the development of the Nrf2 activators industry.
Region Overview:
North America had the highest growth rate of all regions.
Company Overview:
Biogen is one of the major players operating in the Nrf2 Pathway Activators market, holding a share of 82.23% in 2020.
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
Reata Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various life-threatening diseases.
Segmentation Overview:
Among different product types, Dimethyl Fumarate segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Pharmaceutical segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Nrf2 Pathway Activators industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Nrf2 Pathway Activators. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Nrf2 Pathway Activators Market Report Include:
Market Size Estimates: Nrf2 Pathway Activators market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Nrf2 Pathway Activators market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Nrf2 Pathway Activators market
Segment Market Analysis: Nrf2 Pathway Activators market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Nrf2 Pathway Activators market situations and prospects in major and top regions and countries
Nrf2 Pathway Activators Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Nrf2 Pathway Activators Industry Chain: Nrf2 Pathway Activators market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Nrf2 Pathway Activators Industry News, Policies by regions
Nrf2 Pathway Activators Industry Porters Five Forces Analysis
Key players in the global Nrf2 Pathway Activators market are covered in Chapter 2:
Reata Pharmaceuticals
Cayman Chemical Company
BioVision Inc
Biogen
BOC Sciences
Abcam
Biophore
In Chapter 6 and Chapter 9, on the basis of types, the Nrf2 Pathway Activators market from 2018 to 2028 is primarily split into:
Dimethyl Fumarate
4-Octyl Itaconate
Bardoxolone
Other
In Chapter 7 and Chapter 10, on the basis of applications, the Nrf2 Pathway Activators market from 2018 to 2028 covers:
Pharmaceutical
Laboratory
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Nrf2 Pathway Activators market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Nrf2 Pathway Activators industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Nrf2 Pathway Activators market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Nrf2 Pathway Activators industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Nrf2 Pathway Activators market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Nrf2 Pathway Activators market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Nrf2 Pathway Activators market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
